MoneyWorks4Me

Mesco Pharmaceuticals informs about outcome of board meeting

13 Feb 2019 Evaluate

Pursuant to Regulations 30 and 33 of SEBI (LODR) Regulations, 2015, Mesco Pharmaceuticals has informed about submission of the Standalone unaudited Financial Results and Limited Review Report for the quarter ended on 31st December, 2018, duly considered and approved by the Board of Directors in their Board Meeting held on Wednesday, 13th February, 2019 at New Delhi commenced at 02:00 pm and concluded at 02:50 pm.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..